Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2010 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Other Non-Current Assets of $4.9 million for Q1 2026, up 246.35% on a QoQ basis from $1.4 million in Q4 2025, and up 272.48% year-over-year from $1.3 million in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $4.9 million for Q1 2026.
- Quarterly Other Non-Current Assets rose 272.48% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 272.48% YoY) and the FY2025 annual result came in at $1.4 million, down 69.01% from the prior year.
- Other Non-Current Assets was $4.9 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.9 million in Q1 2026 and bottomed at $210000.0 in Q4 2022.
- A 5-year average of $1.6 million and a median of $1.3 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets jumped 2023.81% — and 2025, when it tumbled 69.66%.
- Arrowhead Pharmaceuticals' Other Non-Current Assets stood at $210000.0 in 2022, then climbed by 10.48% to $232000.0 in 2023, then surged by 1228.88% to $3.1 million in 2024, then tumbled by 54.23% to $1.4 million in 2025, then soared by 246.35% to $4.9 million in 2026.
- Business Quant data shows ARWR's Other Non-Current Assets at $4.9 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | 4.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.89 Mn |
| Dec 31, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.46 Mn |
| Mar 31, 2024 | 210,000.00 |
| Dec 31, 2023 | 232,000.00 |
| Sep 30, 2023 | 3.26 Mn |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 210,000.00 |
| Sep 30, 2022 | 218,000.00 |
| Jun 30, 2022 | 275,000.00 |
| Mar 31, 2022 | 275,000.00 |
| Dec 31, 2021 | 273,000.00 |
| Sep 30, 2021 | 272,000.00 |
| Jun 30, 2021 | 272,000.00 |